Proactive Investors - Run By Investors For Investors

MaxCyte prepares for phase I study of potential cancer breakthrough; says trading in line with market expectations

MaxCyte said it is in active discussions with the US Food & Drug Administration to begin the study of MCY-M11
T-cells, part of the body's immune defence, attacking a cancer cell
T-cells, part of the body's immune defence, attacking a cancer cell

MaxCyte Inc (LON:MXCT) said it was in a strong financial position as it prepares for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer disease.

It said it is in active discussions with the US Food & Drug Administration to begin the study of MCY-M11, which is based on its CARMA technology.

WATCH: MaxCyte gearing up for phase I study 

READ: MaxCyte making progress; primed and ready for further advance

MaxCyte believes its discovery will address some of the most significant issues with current CAR-T therapies, including challenging side effects as well as complex and time-consuming manufacturing process.

Promising new way to fight cancer

CAR T-cell therapy is a promising new way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. 

The update came alongside a trading statement from MaxCyte, which also has a commercial arm selling and licensing cell engineering technology.

In the year ended December 31, its revenues were around US$14mln, up 14% on the year earlier. The company said underlying earnings (EBITDA) would be in line with expectations, while it was sitting on US$25.3mln of cash as at the period end.

Progress continues

“We have continued to make significant progress across all areas of the business, particularly with regard to expanding our infrastructure for sales [and] marketing, applications of our products, as well as manufacturing and regulatory, to support our partners as they make advances in developing exciting new classes of medicines,” said chief executive Doug Doerfler.

READ: ‘More of the same, please’: MaxCyte poised for continued growth after solid first half

“We've also made important progress with CARMA, advancing MCY-M11 by filing our IND [investigational new drug] and are on course to dose patients in 2018 in our US-based phase I clinical trial.

“This is a very exciting time for the company and patients as we bring a new generation of CAR-based cancer treatments into the clinic for the first time. We look forward to the future with great confidence."

In late afternoon trading, MaxcCyte shares held steady at 276p.

 -- Adds share price --

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
blood
December 04 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
man coughing
November 10 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use